In the extended session on Monday, the rally for Prime Medicine, Inc. (NASDAQ: PRME) stock persisted, with a noteworthy 5.61% surge after-hours, reaching $6.78. This surge further augmented the rise during regular trading hours, culminating at $6.42, marking a substantial 14.44% increase. The escalation in PRME stock value coincides with an imminent significant event.
- Executive Participation At BioConnect Investor Conference
- Innovative Prime Editing In Focus
- Addressing A Rare Genetic Disorder
Executive Participation At BioConnect Investor Conference
Prime Medicine (PRME) disclosed that its Chief Financial Officer, Allan Reine, M.D., is slated to engage in a fireside chat during the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ, scheduled for Monday, May 20, 2024. Dr. Reine will delve into discussions encompassing the preclinical data showcasing the efficacy of its ex vivo Prime Editing program, PM359.
Innovative Prime Editing In Focus
Recent revelations from Prime Medicine shed light on new data concerning PM359, aimed at rectifying a prevalent disease-causing mutation associated with chronic granulomatous disease (CGD). These findings were presented at an oral session during the American Society of Cell & Gene Therapy 27th Annual Meeting in Baltimore.
Noteworthy is the clearance of PRME's investigational new drug (IND) application for PM359 by the U.S. Food and Drug Administration (FDA) for CGD treatment. This development marks a significant milestone, showcasing the transformative potential of Prime Editing technology.
Addressing A Rare Genetic Disorder
CGD, a rare hereditary ailment, poses significant health challenges, often leading to recurrent and severe infections. The disorder arises from mutations affecting the NADPH oxidase complex, impairing the body's ability to combat infections effectively. Prime Medicine's pioneering ex vivo Prime Editing program, PM359, targets the correction of the predominant mutation in CGD patients' CD34+ hematopoietic stem cells (HSCs), with promising results observed in preclinical studies.
The restoration of neutrophil function post-stem cell engraftment in animal models underscores the therapeutic potential of this innovative approach, signaling hope for patients grappling with this debilitating condition. Notably, results showed that neutrophil function could be restored in mice following stem cell engraftment and that Prime Edited cell output could be increased to a therapeutic size.
在週一的延期交易中,Prime Medicine, Inc.(納斯達克股票代碼:PRME)的股票持續上漲,盤後大幅上漲了5.61%,達到6.78美元。這種飆升進一步加劇了常規交易時段的漲幅,最終達到6.42美元,大幅上漲了14.44%。PRME股票價值的上漲恰逢即將發生的重大事件。
- 高管參加 BioConnect 投資者大會
- 聚焦創新 Prime 編輯
- 解決一種罕見的遺傳性疾病
高管參加 BioConnect 投資者大會
Prime Medicine(PRME)透露,其首席財務官艾倫·雷因醫學博士計劃在定於2024年5月20日星期一在納斯達克舉行的H.C. Wainwright第二屆年度BioConnect投資者會議上進行爐邊談話。Reine博士將深入探討包括臨床前數據的討論,這些數據展示了其體外Prime編輯計劃 PM359 的功效。
聚焦創新 Prime 編輯
Prime Medicine 最近披露的消息揭示了有關 PM359 的新數據,旨在糾正與慢性肉芽腫病 (CGD) 相關的流行致病突變。這些發現是在巴爾的摩舉行的美國細胞與基因療法學會第27屆年會期間的口頭會議上發表的。
值得注意的是,美國食品藥品監督管理局(FDA)批准了PRME的用於CGD治療的 PM359 研究性新藥(IND)申請。這一發展標誌着一個重要的里程碑,展示了Prime Editing技術的變革潛力。
解決一種罕見的遺傳性疾病
CGD 是一種罕見的遺傳性疾病,構成了嚴重的健康挑戰,通常會導致反覆出現的嚴重感染。這種疾病源於影響NADPH氧化酶複合物的突變,損害了人體有效抵抗感染的能力。Prime Medicine 開創性的體外主要編輯計劃 PM359 旨在校正CGD患者CD34+造血幹細胞(HSC)中的主要突變,臨床前研究中觀察到令人鼓舞的結果。
在動物模型中植入幹細胞後,中性粒細胞功能的恢復凸顯了這種創新方法的治療潛力,爲努力應對這種使人衰弱的疾病的患者帶來了希望。值得注意的是,結果表明,幹細胞移植後小鼠的中性粒細胞功能可以恢復,Prime Edited的細胞產量可以增加到治療規模。